Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.45 |
| ▸ | GLP1R | P43220 | 3/20 | 0.45 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.45 |
| ▸ | ECE1 | P42892 | 1/20 | 0.45 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | RXFP4 | Q8TDU9 | 1/20 | 0.44 |
| ▸ | RXFP3 | Q9NSD7 | 1/20 | 0.44 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723350 | 0.99 | OPRM1 (0.46) | OPRM1OPRD1OPRK1CTSBCTSK | |
| SCHEMBL14404862 | 0.96 | OPRM1 (0.49) | OPRM1OPRD1OPRK1CTSBCTSK | |
| SCHEMBL13723426 | 0.96 | OPRM1 (0.49) | OPRM1OPRD1OPRK1CTSBCTSK | |
| SCHEMBL16318406 | 0.94 | OPRM1 (0.47) | OPRM1OPRD1OPRK1CTSBCTSK | |
| SCHEMBL13723021 | 0.94 | KISS1R (0.50) | OPRM1OPRD1OPRK1CTSBCTSK | |
| SCHEMBL16358284 | 0.94 | OPRM1 (0.49) | OPRM1OPRD1OPRK1CTSBCTSK | |
| SCHEMBL13724356 | 0.94 | OPRM1 (0.49) | OPRM1OPRD1OPRK1CTSBCTSK | |
| SCHEMBL13723676 | 0.93 | OPRM1 (0.48) | OPRM1OPRD1OPRK1CTSBCTSK | |
| SCHEMBL13723042 | 0.92 | OPRM1 (0.54) | OPRM1OPRD1OPRK1VIPR1GLP1R | |
| SCHEMBL16358283 | 0.92 | CTSB (0.48) | OPRM1OPRD1OPRK1CTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | OPRM1 1981/4885OPRD1 2570/4885OPRK1 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.